Bausch Health, after waylaying other copycats of its irritable bowel syndrome diarrhea (IBS-D) drug Xifaxan, has been dealt a blow in court. The court order potentially creates an opening for Norwich ...
Clinical Trials Arena on MSN
Bausch Health’s new formulation of Xifaxan fails pair of Phase III trials
Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap the ...
As an essential component of the drug development process, human clinical trials assist in determining whether a given drug will serve its intended purpose, but patent applicants should consider ...
The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation. The FDA's tentative approval of rifaximin 550 mg ...
A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Rifaximin ...
Please provide your email address to receive an email when new articles are posted on . CHARLOTTE, N.C. — Daily treatment with Xifaxan over 2 weeks improved stool consistency and fecal urgency in ...
Most Medicare Part D prescription drug plans and Medicare Advantage plans with drug coverage include rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea (IBS-D) and overt hepatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results